RT Journal Article
SR Electronic
T1 Impact of <em>APOE</em> genotype on cognition in idiopathic and genetic forms of Parkinson’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.06.22281991
DO 10.1101/2022.11.06.22281991
A1 Koros, Christos
A1 Brockmann, Kathrin
A1 Simitsi, Athina-Maria
A1 Bougea, Anastasia
A1 Liu, Hui
A1 Hauser, Ann-Kathrin
A1 Schulte, Claudia
A1 Lerche, Stefanie
A1 Pachi, Ioanna
A1 Papagiannakis, Nikolaos
A1 Antonelou, Roubina
A1 Zahou, Athina
A1 Wurster, Isabel
A1 Efthymiopoulou, Efthymia
A1 Beratis, Ion
A1 Maniati, Matina
A1 Moraitou, Marina
A1 Michelakakis, Helen
A1 Paraskevas, Georgios
A1 Papageorgiou, Sokratis G.
A1 Potagas, Constantin
A1 Papadimitriou, Dimitra
A1 Bozi, Maria
A1 Stamelou, Maria
A1 Gasser, Thomas
A1 Stefanis, Leonidas
YR 2022
UL http://medrxiv.org/content/early/2022/11/10/2022.11.06.22281991.abstract
AB Background Apolipoprotein E-ε4 (APOE ε4) genotype may be associated with the development of cognitive decline in idiopathic Parkinson’s disease i(PD), however its effect in genetic PD is understudied.Objectives In the current work we aimed to assess the impact of APOE genotype on cognition in iPD as well as in genetic PD with mutations in the Alpha-synuclein (SNCA) and Glycocerebrosidase (GBA1) genes.Methods Two independent PD cohorts were analyzed: The first cohort (Athens) included 50 iPD patients, 35 patients with the p.A53T SNCA mutation and 59 patients with GBA1 mutations (13 mild /46 severe). The second cohort (Tübingen) included 292 patients with GBA1 mutations (170 risk/ 52 mild/ 70 severe). All patients underwent cognitive testing and were genotyped for APOE.Results In the iPD subgroup, carriers of at least one APOE ε4 exhibited lower Montreal Cognitive Assessment test (MoCA) score as compared to non-carriers (p=0.044). Notably, in the p.A53T SNCA subgroup, APOE ε4 carriers also had lower MoCA scores compared to non-carriers (p=0.039). There were no APOE ε4-related differences in the two GBA1 subgroups (Athens, p=0.729; Tübingen p=0.585).Conclusions We confirm the impact of APOE ε4 on cognitive decline in iPD and for the first time report a similar effect in p.A53T SNCA mutation carriers, who represent the prototypical genetic synucleinopathy. Contrary, the lack of such an effect in two independent cohorts of GBA1 mutation carriers, who are thought to also manifest a predominant alpha-synuclein-driven cognitive decline, suggests differences in factors associated with cognitive dysfunction between different genetic forms of synucleinopathies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially funded by the National Network for Neurodegenerative Diseases (ΕΔΙΑΝ) (GSRT).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Eginition Hospital Ethics Committee Ethical Aproval was granted by the EC for the conduction of the study as a part of Thalis Parkinson's disease database I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors